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Pure monoclinic calcium pyrophosphate dihydrate (m-CPPD) has been
synthesized and characterized by synchrotron powder X-ray diffraction and
neutron diffraction. Rietveld refinement of complementary diffraction data has,
for the first time, allowed the crystal structure of m-CPPD to be solved. The
monoclinic system P21/n was confirmed and unit-cell parameters determined: a=
12.60842 (4), b = 9.24278 (4), c = 6.74885 (2) A˚ and  = 104.9916 (3). Neutron
diffraction data especially have allowed the precise determination of the
position of H atoms in the structure. The relationship between the m-CPPD
crystal structure and that of the triclinic calcium pyrophosphate dihydrate (t-
CPPD) phase as well as other pyrophosphate phases involving other divalent
cations are discussed by considering the inflammatory potential of these phases
and/or their involvement in different diseases. These original structural data
represent a key step in the understanding of the mechanisms of crystal
formation involved in different types of arthritis and to improve early detection
of calcium pyrophosphate (CPP) phases in vivo.
1. Introduction
Calcium pyrophosphate hydrates (CPP; Ca2P2O7nH2O) are,
together with calcium orthophosphates, the most common
calcium salt crystals found in pathological osteo-articular
cartilage and meniscii (MacMullan et al., 2011). They have
been reportedly found in the joints of patients suffering from
several types of arthritis, including osteoarthritis and calcium
pyrophosphate crystal deposition disease, also known as
pseudo-gout (Jones et al., 1992; Ea et al., 2011). Although the
physico-chemical reactivity and crystal structure of synthetic
and biological calcium orthophosphate crystals have been
largely studied, those of calcium pyrophosphate crystals have
been much less investigated and remain not fully understood
mainly owing to difficulties in preparing pure CPP crystals and
the lack of biological applications of these phases (Pritzker,
1998). To date, two different types of CPP crystals have been
identified in joint tissues of arthritic patients: monoclinic and
triclinic calcium pyrophosphate dihydrate (CPPD:
Ca2P2O72H2O) crystals, also known as m-CPPD and t-CPPD,
respectively (Liu et al., 2009). They could both be detected in
non-inflammatory osteoarthritic joints but also appear to
induce an inflammatory response during in vivo and in vitro
experiments (Roch-Arveiller et al., 1990; Swan et al., 1995).
Although the biological events related to the inflammatory
potential of CPP crystals have been studied, the chemical and
physico-chemical interactions between the crystals and
biological tissues or cells remain unknown (Roch-Arveiller et
al., 1990; Winternitz et al., 1996; Liu et al., 2009). A proposed
mechanism, supported by DFT calculation, involves the
rupture of lysosome phospholipid membranes in cells, which is
induced by pyrophosphate groups on the surface of the crys-
tals; however, the biological effects could also depend on the
crystal structure of the phases as well as on the morphology of
the crystals, much in the same way as for other solid phases
(Mandel, 1976; Roch-Arveiller et al., 1990; Swan et al., 1995;
Wierzbicki et al., 2003).
Currently, the crystal structure of m-CPPD remains
unknown and very few crystallographic data are available. To
the best of our knowledge, since its first identification in the
joints of arthritic patients by Kohn et al., only six powder
X-ray diffraction (XRD) patterns of this phase have been
published, from both synthetic and ex vivo samples (Kohn et
al., 1962; Brown et al., 1963; Mandel et al., 1988; Swan et al.,
1995; Liu et al., 2009; Gras, Rey et al., 2013). Early works
allowed the determination of the crystallization system
(monoclinic, P21/n space group) by Brown et al. leading to the
widely accepted notation m-CPPD. In addition, Mandel et al.
determined the m-CPPD cell parameters (Brown et al., 1963;
Mandel et al., 1988). To the best of our knowledge, these are
the only cell parameters available in previously published
reports. Based on these data, an indexing of the most intense
XRD peaks of the m-CPPD pattern has been proposed
(Mandel et al., 1988). Recently, Gras, Rey et al. (2013) showed
that the patterns obtained for pure phase powders of m-CPPD,
synthesized using a new method, were in good agreement with
the data published by Brown et al. and by Liu et al. but they
did not correspond to the lattice parameter determined by
Mandel et al. (Brown et al., 1963; Mandel et al., 1988; Liu et al.,
2009; Gras, Rey et al., 2013). Gras, Rey et al. (2013) reported
different unit-cell parameters, which were determined by the
Rietveld refinement of a pure-phase m-CPPD powder XRD
pattern. A first attempt to resolve the crystal structure of m-
CPPD based on a comparison with other fully identified
monoclinic pyrophosphate dihydrate structures, such as
magnesium, cobalt, iron and manganese pyrophosphate
dihydrates showing very similar cell parameters and atomic
organization, did not lead to satisfactory convergence. The
authors concluded that the m-CPPD crystal structure could be
significantly different to those of the other dihydrated pyro-
phosphate compounds (Schneider & Collin, 1973; Oka &
Kawahara, 1982; Effenberger & Pertlik, 1993; Giesber et al.,
2000).
Thus, even though m-CPPD has been identified in arthritic
joints since 1962, its crystal structure has not yet been resolved
(Kohn et al., 1962; Liu et al., 2009). A full structural description
of this phase could, however, greatly improve the under-
standing of its inflammatory potential, which is recognized as
the highest among the crystalline hydrated CPP phases (Roch-
Arveiller et al., 1990).
The objective of the present study is to resolve the crystal
structure of m-CPPD from powder patterns by combining
experimental synchrotron X-ray diffraction, neutron diffrac-
tion techniques and Rietveld refinement methods. The rela-
tionship between the resolved m-CPPD crystal structure and
that of the t-CPPD phase, as well as of other pyrophosphate
phases involving other divalent cations, will be discussed
considering the inflammatory potential of these phases or
their involvement in diseases.
2. Experimental
2.1. Synthesis of m-CPPD powder
Based on recently published results for the synthesis of
hydrated CPP phases (Gras, Rey et al., 2013), a large amount
of pure phase m-CPPD powder was obtained by a double-
decomposition reaction between potassium pyrophosphate
and calcium nitrate salt solutions at pH 5.8 and 363 K. Char-
acterization of the as-synthesized m-CPPD powder, in terms
of composition, crystal structure and purity, was performed by
chemical analyses, FTIR and Raman spectroscopies, XRD on
laboratory equipment, scanning electron microscopy and
thermogravimetric analyses; the results have already been
published elsewhere (Gras, Rey et al., 2013).
2.2. Powder X-ray diffraction analysis
Powder XRD patterns were acquired on the two-circle
diffractometer of the Cristal beamline at the SOLEIL
synchrotron (Gif-sur-Yvette, France) as part of the project
"Structural investigations on hydrated calcium pyrophosphate
phases of biological interest: Study on synthetic and biological
samples" (Proposal No. 20130932, Cristal beamline, 19–22
February 2014). A monochromatic beam was selected, using a
Si (111) double-crystal monochromator, and its wavelength
(0.72442 A˚) was determined using NIST standard LaB6. The
powder sample was placed in a 0.7 mm-diameter special glass
capillary mounted on a spinner to improve averaging. High
angular resolution was obtained with the 21 perfect Si (111)
crystal rear analyser mounted on a two-circle diffractometer.
The detector was made of YAP, CeBr3 scintillators Maxipix2.
2.3. Powder neutron diffraction analysis
The powder neutron diffraction patterns were acquired on
the PYRRHIAS diffractometer of the G4-1 line at the Orphe´e
reactor (Gif-sur-Yvette, France). AG4 cold neutron beam was
used with a wavelength of  = 2.423 A˚. The m-CPPD powder
sample was placed in a container that measures 8 mm 
50 mm under a primary vacuum. The G4-1 apparatus
consisted of a two-circle diffractometer, comprising a pyrolytic
graphite monochromator (002) and a multi-detector of 800
BF3 counter-cells covering 80
 in 0.1 steps.
2.4. Rietveld refinement of powder diffraction patterns
A thorough Rietveld refinement analysis combining X-ray
and neutron powder diffraction data has been performed for
the full solution of the m-CPPD crystal structure.
The powder XRD pattern was indexed using the LSI
method implemented in TOPAS using a monoclinic system of
extension class P21/n (Coelho, 2003, 2009). TOPAS was used
to solve the m-CPPD crystal structure and FULLPROF was
used to refine the crystal structure (Rodrı´guez-Carvajal, 2001;
Coelho, 2009).
As the resolution of the G4-1 neutron diffractometer was
not sufficient to determine a full crystal structure solution, the
neutron diffraction data were used to validate the refined
structure parameters obtained with XRD data and to more
precisely determine the position of the H atoms in the crystal
structure. Heavy atom positions (Ca, P and O1–O7) were
determined by refinement of XRD data. Heavy-atom posi-
tions were then refined as a best compromise between both
XRD and neutron powder diffraction analyses, whereas H-
atom positions were only refined based on neutron diffraction
data.
3. Results and discussion
Characterization of the synthesized powder confirmed the
composition and purity of the m-CPPD powder sample as
being the same as that reported by Gras et al. (2013a). In the
absence of any suitable single crystals despite various synth-
esis conditions being reported and assayed, crystal structure
determination was performed by powder XRD analysis (Kohn
et al., 1962; Brown et al., 1963; Mandel et al., 1984, 1988; Swan
et al., 1995; Liu et al., 2009; Gras, Rey et al., 2009; Gras,
Teychene´ et al., 2013). The refined X-ray diffraction and
neutron diffraction patterns are presented in Figs. 1 and 2,
respectively.
Indexing the XRD data using the LSI method led to a
monoclinic cell with figures of merit
(FoM) of M20 = 173 and F20 = 614,
which are in good agreement with
previously published data (de
Wolff, 1968; Smith & Snyder, 1979;
Coelho, 2003; Gras, Rey et al.,
2013). The intensities were
extracted from the powder XRD
pattern using the Le Bail method
(Le Bail, 2005). The initial model
for m-CPPD crystal structure
refinement was obtained from
TOPAS software using simulated
annealing in direct space. Profile
fitting using FULLPROF software
confirmed the cell parameters and
structural solution (Fig. 1, Table 1)
(Rodrı´guez-Carvajal, 2001).
The solved m-CPPD crystal
structure presents molecular
groups that correspond to pyro-
phosphate ions and two water
molecules, as expected (Fig. 3).
Each formula unit of
Ca2P2O72H2O is repeated four
times per cell, leading to a volume
per formula unit of 189.93 (1) A˚3
(Table 1). This volume is almost
equal to the volume per formula
unit of the t-CPPD crystal struc-
ture, 189.32 (9) A˚3, which is the
other CPPD phase encountered in
pathological joints, which presents
a high inflammatory potential
(Mandel, 1975).
The distances and configurations
of different molecules and coordi-
nation sets obtained after Rietveld
refinement (Table 2, Fig. 3) appear
to be consistent with the environ-
ments of calcium ions in both types
of molecules; however, there is a
slight deformation in the group
Figure 1
Rietveld refinement diagram based on synchrotron X-ray diffraction data of m-CPPD. Experimental
synchrotron X-ray diffraction data are shown in red, simulated diagram in black and the difference
between the two diagrams in blue; vertical green lines indicate the Bragg peak positions.
Figure 2
Rietveld refinement diagram based on neutron powder diffraction data of m-CPPD. Experimental
neutron powder diffraction data are shown in red, simulated diagram in black and the difference between
the two diagrams is shown in blue; vertical green lines indicate the Bragg peak positions.
involving the P2 atom of the pyrophosphate molecule. The
P1—O7—P2 angle of 128.3 (5) is close to the value estimated
by FTIR analysis (126) (Gras et al., 2013a). The twists
between end groups correspond to a dichromate configura-
tion, such as that found in the t-CPPD (Fig. 4) and the
monoclinic calcium pyrophosphate tetrahydrate  (-m-
CPPT) crystal structures (Davis et al., 1985).
During the course of the refinement of the XRD data, the
distances within the water molecules were restricted in order
to prevent the H atoms from inconsistently departing from
their associated O atoms. This leads to water molecules with
H—O—H angles of 123 (6) and 93 (5), which are slightly
Figure 4
Crystal structure of the t-CPPD phase along the [001] axis showing
pyrophosphate anions oriented on (110) and the hydrogen bonding as
dashed lines (Mandel, 1975).
Figure 3
(a) Crystal structure of the m-CPPD phase and (b) representation of m-
CPPD crystal structure showing the hydrogen-bond network. Displace-
ment ellipsoids are drawn at the 50% probability level.
Table 2
Selected geometric parameters (A˚, ).
P1—O1 1.492 (9) Ca1—O5i 2.257 (6)
P1—O2 1.551 (8) Ca1—OW1 2.360 (12)
P1—O3 1.510 (11) Ca1—O1 2.372 (7)
P1—O7 1.688 (9) Ca1—O2ii 2.386 (8)
P2—O4 1.501 (8) Ca1—O4 2.429 (6)
P2—O5 1.525 (9) Ca1—O6iii 2.514 (9)
P2—O6 1.533 (9) Ca1—O4iii 2.648 (9)
P2—O7 1.581 (9) Ca2—O2ii 2.334 (6)
OW1—H1 0.97 (7) Ca2—O6ii 2.343 (8)
OW1—H2 0.89 (7) Ca2—O3iv 2.353 (8)
OW2—H3 0.99 (8) Ca2—OW2 2.359 (12)
OW2—H4 1.23 (6) Ca2—O1iii 2.412 (10)
Ca2—O4 2.472 (8)
O1—P1—O3 112.7 (6) O4—P2—O5 114.7 (5)
O1—P1—O2 113.4 (4) O4—P2—O6 106.2 (4)
O1—P1—O7 107.0 (4) O4—P2—O7 109.9 (4)
O2—P1—O3 116.4 (5) O5—P2—O6 113.3 (5)
O2—P1—O7 104.2 (4) O5—P2—O7 106.4 (4)
O3—P1—O7 101.5 (4) O6—P2—O7 106.0 (4)
P1—O7—P2 128.3 (5) H4—OW2—H3 93 (5)
H2—OW1—H1 123 (6)
O3—P1—P2—O5 22.7 (7) O6—P1—P2—O2 ÿ16.7 (5)
O1—P1—P2—O4 9.3 (5)
Symmetry codes: (i) xÿ 12 ;ÿyþ
3
2 ; zÿ
1
2; (ii) x; y; zÿ 1; (iii) ÿxþ 1;ÿyþ 1;ÿz þ 1;
(iv) xþ 12 ;ÿyþ
3
2 ; zÿ
1
2.
Table 1
Experimental details.
XRD Neutron diffraction
Crystal data
Chemical formula Ca2H4P2O9 Ca2H4P2O9
Mr (g mol
ÿ1) 290.13 290.13
a, b, c (A˚) 12.60842 (4), 9.24278 (4),
6.74885 (2)
12.5840 (14), 9.2184 (10),
6.7372 (7)
 () 104.9916 (3) 104.949 (11)
V (A˚3) 759.72 (1) 755.09 (15)
Z 4 4
Radiation type X-ray ( = 0.72442 A˚) Neutron (A˚ = 2.423 A˚)
Specimen White powder White powder
Data collection
Diffractometer Cristal beamline
(Soleil synchrotron)
G4-1 line
(Orphe´e reactor)
Specimen mounting 0.7 mm capillary 8 mm  50 mm container
2 values () 2min = 0.020 2min = 7.02
2max = 50.000 2max = 86.92
2step = 0.004 2step = 0.10
Refinement
R factors Rp = 0.0415 Rp = 0.0142
Rwp = 0.0534 Rwp = 0.0196
Rexp = 0.0208 Rexp = 0.0009
RBragg = 0.0553 RBragg = 0.0690
Goodness of fit 2 = 6.607 2 = 4.857
No. of data points 12495 800
Computer programs: FULLPROF (Rodrı´guez-Carvajal, 2001).
more open than those observed in the other crystal structures
for hydrated pyrophosphate compounds [from 95 (2) to
115 (3)], and H—OW distances close to 1 A˚ confirm the
hydrogen-bonding network proposed (Mandel, 1975; Balic´-
Zˇunic´ et al., 2000). The resolution of the acquisition and the
Bragg factor, however, led to us taking the values for the
positions of the H atoms from XRD refinements with caution.
A complementary analysis based on a neutron powder
diffraction pattern (Fig. 2 and Table 1) was then used to refine
the positions of the H atoms in the structure.
Pyrophosphate anions are oriented on the (010) plane with
alternation in the direction of these anions with respect to the
c axis, due to the inversion centre (Fig. 3). The cohesion of the
crystal structure following the b axis seems to be based on
alternating coordination and hydrogen bonds. This organiza-
tion is close to the organization of the t-CPPD phase (Mandel,
1975). The main difference lies in the apparent translation of a
formula unit in the t-CPPD crystal structure along ½110,
disturbing the alternation of pyrophosphate molecules
following the c axis and forming a more compact arrangement
of the unit formula. The hydrogen network was then modified
and could explain the slight difference in volume observed
between t-CPPD and m-CPPD (Figs. 3 and 4). It should be
noted that the c axis used for both representations of t-CPPD
and m-CPPD corresponds to the main crystal dimension for
each phase, as determined by electron diffraction (Gras, 2014).
In addition to the crystal habit which is different for the two
CPPD polymorphs (thin needles for m-CPPD and rods for t-
CPPD), the different arrangements of pyrophosphate groups
on the surface planes, as observed by electron diffraction,
could explain the difference in inflammatory potential
reported during in vitro and in vivo tests (Roch-Arveiller et al.,
1990; Swan et al., 1995). The m-CPPD crystals present a higher
inflammatory potential than t-CPPD crystals, which could be
attributed to an interaction between the crystal surface and
molecules or cells in the biological tissue/medium. A
morphological study is currently in progress investigating the
morphology of m-CPPD and t-CPPD crystals by imple-
menting ab initio modelling using the Bravais–Friedel–
Donnay–Harker (BFDH) theory and experimental transmis-
sion electron microscopy to further characterize the various
crystal faces. A proposed mechanism, involving the rupture of
lysosome phospholipid membranes induced by pyrophosphate
groups on the surface of the crystals, could then explain the
difference in inflammatory potential (Mandel, 1976; Roch-
Arveiller et al., 1990; Swan et al., 1995; Wierzbicki et al., 2003).
In addition, although closer to the t-CPPD crystal structure,
the m-CPPD crystal structure presents some similarities to
other dihydrated pyrophosphate compounds, such as
Mg2P2O72H2O (Oka & Kawahara, 1982), Co2P2O72H2O
(Effenberger & Pertlik, 1993), Fe2P2O72H2O (Giesber et al.,
2000) and Mn2P2O72H2O (Schneider & Collin, 1973). For
better clarity of this comparison, we have shown all of these
crystal structures in a P21/n space group in Fig. 5, which were
obtained by symmetry operations in accordance with the
Co2P2O72H2O crystal structure; their respective unit-cell
parameters are reported in Table 3 (Effenberger & Pertlik,
1993). These crystal structures present an alternation of
pyrophosphate molecules, clearly shown on a representation
following the a axis. The formula unit X2P2O72H2O is repe-
ated following two perpendicular axes with different orienta-
tions, rotating to 180 or 90 from one unit to the next (Fig. 6).
It is interesting to note that the a axis is still the main axis in
the crystals studied, the pyrophosphate organization is similar
to the one on the basal face of the m-CPPD crystals
(Schneider & Collin, 1973; Giesber et al., 2000).
These similarities to other pyrophosphate compound
phases could be of interest for studies on the formation and
evolution of CPP crystals in vitro and in vivo. Based on the
Mandel et al. protocol, magnesium ions were involved in the
synthesis of m-CPPD, whereas they were not in the synthesis
of t-CPPD (Mandel et al., 1988; Groves et al., 2007). In addi-
tion, it is known that two of these ions, iron and magnesium,
are indeed associated with diseases, hypomagnesaemia and
haemochromatosis, which are related to premature osteo-
arthritis (Jones et al., 1992; Wright & Doherty, 1997). The
Figure 5
Crystal structures of various pyrophosphate phases: (a) Mg2P2O72H2O
(Oka & Kawahara, 1982), (b) Co2P2O72H2O (Effenberger & Pertlik,
1993), (c) Fe2P2O72H2O (Giesber et al., 2000) and (d) Mn2P2O72H2O
(Schneider & Collin, 1973).
Table 3
Unit-cell parameters of various metal pyrophosphate dihydrates.
Mg2P2O72H2O (Oka & Kawahara, 1982), Co2P2O72H2O (Effenberger &
Pertlik, 1993), Fe2P2O72H2O (Giesber et al., 2000) and Mn2P2O72H2O
(Schneider & Collin, 1973). The metal atomic radii are given as indicative data
(Shannon & Prewitt, 1969; Shannon, 1976). All structures in space group P21/n
( and  = 90).
a (A˚) b (A˚) c (A˚)  () V (A˚3) r (A˚)
Mg2P2O72H2O 6.277 (1) 13.906 (2) 7.367 (1) 94.37 (2) 641.2 0.86
Co2P2O72H2O 6.334 (1) 13.997 (3) 7.376 (1) 94.77 (3) 651.7 0.89
Fe2P2O72H2O 6.400 (2) 14.181 (3) 7.416 (1) 95.43 (2) 670.1 0.92
Mn2P2O72H2O 6.461 (2) 14.325 (4) 7.570 (4) 95.20 (4) 674.7 0.97
similarities between the m-CPPD phase and other pyropho-
sphate phases involving other divalent metal cations could
show the influence of these ions and other ions, such as Cu2+
involved in Wilson’s disease, on diseases associated with
polyarthritis from a structural viewpoint (McClure & Smith,
1983).
4. Conclusions
The crystal structure of the m-CPPD phase has been resolved
based on the Rietveld refinement of original synchrotron
powder X-ray diffraction data and neutron powder diffraction
data for a pure m-CPPD sample that was synthesized.
Providing these new structural data is of particular importance
to further understand the role of m-CPPD crystals, which are
encountered in vivo in the joints of arthritic patients during
the development of the disease. These results could be used to
thoroughly study the physico-chemical and inflammatory
properties of calcium pyrophosphate crystals based on surface
properties and polymorphism of calcium pyrophosphate
dihydrates. In addition, they also contribute in the improve-
ment of the detection and identification of arthritic calcifica-
tions by X-ray diffraction analysis.
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